Navigation Links
Failing to Demonstrate Value of Innovation is Top Risk Facing Life Sciences Sector, According to Ernst & Young
Date:4/23/2009

NEW YORK, April 23 /PRNewswire/ -- Government and private insurers are placing unprecedented pressures on Life Sciences companies to demonstrate value for the products they develop, according to The 2009 Ernst & Young business risk report, Life sciences. Insurers, governments and individuals are likely to increase demands to demonstrate value in the years ahead, as they confront mounting healthcare costs, a shrinking tax base, aging populations, and a mandate to provide care for a larger pool of citizens.

Meeting this challenge tops the list of the 10 most pressing risks facing the Life sciences industry in 2009, according to the report. Like most of the issues that comprise the list, the need to meet increasingly stringent demands for reimbursement has been exacerbated by the global economic downturn, which is challenging the high-risk/ high-reward model that companies have used to fund drug development efforts for several decades. The economy has prompted large and small companies to sharpen their focus on how they manage scarce capital, boost research and development productivity, and in some cases reinvent a long-held business model to build long-term shareholder value.

"This is a time of great upheaval in the pharma industry and it is intensified by the global financial crisis. Companies are looking with renewed vigor at how they manage the risks at the very core of their businesses," said Carolyn Buck Luce, Global Pharmaceutical Sector Leader at Ernst & Young. "But risk brings opportunity and the definition of crisis is 'the crucial stage or turning point.' This moment provides the industry with a chance to not only confront these immediate risks, but to take the actions that will strengthen their organizations in more fundamental ways as well."

In the biotech sector, the relative scarcity of capital to support drug development has placed new strains on the industry's traditional business mode
'/>"/>

SOURCE Ernst & Young
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Demonstrates Impressive Results in Higher Risk Patients
2. Scientists demonstrate laser with controlled polarization
3. Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth
4. Finesse Demonstrates TruFluor(TM) pH, a Single-Use Optical pH Sensor and Transmitter
5. VAP Test Demonstrates Value of Fish Oil in Reducing Heart Risk for Super Bowl Champs
6. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
7. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
8. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program
9. Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
10. Sparta Systems Demonstrates Global Enterprise Quality Management Leadership at TrackWise(R) Connection User Conferences
11. Human clinical study demonstrates superior Neptune Krill Oil NKO(R) pharmacokinetic profile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently ... Supplements Pre-Conference seminar on probiotics in San Diego, CA. ... education conference for health care professionals. This year’s pre-conference seminar ... probiotics in health. Dr. Leyer spoke about the emerging topics ...
(Date:1/22/2015)... BRUNSWICK , Nueva Jersey , 22 de ... Award for Biomedical Research abre hoy su llamada a ... personas cuya investigación científica ha hecho, o tiene el ... la salud humana. Las nominaciones se aceptarán hasta el ...
(Date:1/22/2015)...  Derma Sciences, Inc. (Nasdaq: DSCI ), ... care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic allografts ... the Premier, Inc. Regenerative Skin Grafting contract portfolio. ... and AMNIOMATRIX® product lines, which continue to be ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... , ... announced that its Oragene®•DNA product has been selected by Prometheus as the sample collection ... for this type of genetic testing service as it solves sample collection challenges inherent ... ...
... SUNRISE, Fla., Aug. 18 Bioheart, Inc., (OTC ... and biologics that help monitor, diagnose and treat heart failure ... Directors have joined the Company,s executive management team. In addition ... of Directors, Karl E. Groth, Ph.D., became the Chief Executive ...
... , , BOSTON, Aug. 18 ... is pleased to host their September Congress taking place at the ... economic climate, with heightened M & A activity in the pharma ... governance has become more critical," says Sharon Langan, Senior Program Manager, ...
Cached Biology Technology:DNA Genotek Sample Collection Kit Selected by Prometheus for MyCeliacID™ Genetic Test 2DNA Genotek Sample Collection Kit Selected by Prometheus for MyCeliacID™ Genetic Test 3Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry 2Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry 3Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry 4Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry 5Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry 6Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry 7CBI Hosts 5th Annual Pharma/Biotech Enterprise Governance, Risk and Controls Congress 2
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology used for ... overall facial feature of a person such as nose, ...
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays a role ... Hypertension – the medical term for high blood pressure – ... and the inflatable cuff that,s used in measuring blood pressure ... there,s nothing new about hypertension, its triggers and its effects. ...
(Date:12/10/2014)... a leader in performance biometric data sensor technology, today ... licensees for highly accurate, clinically validated biometric technology. This ... fitness and health sectors, but first responders/military and gaming ... as useful as the biometric data it delivers. As ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... promising new vaccine against a pre-cancerous cervical virus shows ... cancer, according to a study presented today during the ... Cancer Prevention Research meeting in Baltimore. , ... in early October, confirmed the vaccine's efficacy from available ...
... Grand Challenges in Global health initiative to genetically engineer ... aid in testing the safety and effectiveness of potential ... Foundation, the Yale project will be headed by Richard ... at Yale University School of Medicine, and Howard Hughes ...
... gene enabling an insect virus to enter new cells was ... virus's use, researchers at Boyce Thompson Institute (BTI) at Cornell ... group of viruses that can liquefy their insect hosts in ... a sneeze in mammals, as potential pesticides. But the viruses ...
Cached Biology News:Updated data on novel HPV vaccine confirms efficacy in large population 2Grand Challenges in Global Health initiative funds Yale project 2Stolen gene allows insect virus to enter cells 2Stolen gene allows insect virus to enter cells 3
Homo sapiens olfactomedin 1, transcript variant 3...
RABBIT ANTI QUINOLINIC ACID...
Coverslips for Microarrays, 1. *Category: MICROARRAY ACCESSORIES....
Agarase cleaves agarose to neoagaro-oligosaccharides, and is used for,quantitative, gentle recovery of DNA from low melting point agarose....
Biology Products: